Abatacept as GVHD Prophylaxis Phase 2

PHASE2CompletedINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

June 30, 2018

Study Completion Date

March 31, 2024

Conditions
Graft vs Host DiseaseMalignancy
Interventions
DRUG

Abatacept

Arm B-investigational prophylaxis with abatacept, a calcineurin inhibitor and methotrexate

DRUG

placebo

Trial Locations (14)

20010

Children's National Medical Center, Washington D.C.

30322

Children's Healthcare of Atlanta at Egleston, Atlanta

Emory University/Winship Cancer Center, Atlanta

32610

University of Florida, Gainesville

45229

Michael Grimley, Cincinnati

48109

University of Michigan, Ann Arbor

63141

Washington University, St Louis

80045

Children's Hospital Colorado, Aurora

84113

University of Utah, Salt Lake City

90027

Children's Hospital Los Angeles, Los Angeles

94609

UCSF Benioff Children's Hospital Oakland, Oakland

98101

Seattle Cancer Care Alliance, Seattle

02115

Dana-Farber Cancer Institute, Boston

V6H 3V4

Children's and Women's Health Center of BC, Vancouver

All Listed Sponsors
collaborator

FDA Office of Orphan Products Development

FED

lead

Boston Children's Hospital

OTHER

NCT01743131 - Abatacept as GVHD Prophylaxis Phase 2 | Biotech Hunter | Biotech Hunter